Celyad Oncology announced on Monday that it is suspending a cancer therapy trial to investigate the deaths of two patients. This is a treatment administered to patients with refractory metastatic colorectal cancer, specifies the Guibertine company in a press release.
She decided “to voluntarily suspend treatment and recruit patients into the study, in order to investigate these two deaths. Celyad Oncology is currently analyzing these two cases and evaluating any other potential similar events in other patients treated in this study.“.
The company’s price was down more than 13% on Monday morning on the Brussels Stock Exchange, following this announcement.
